Prelude Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Prelude Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,700	Closed	-$11K	–	2300
2020 Q3	$11K	Sell	2,700 -100	-4%	-$367	﹤0.01%	1453
2020 Q2	$9K	Buy	+2,800	New	+$9.56K	﹤0.01%	1612
2020 Q1	–	Sell	-6,699	Closed	-$21K	–	2325
2019 Q4	$21K	Sell	6,699 -6,455	-49%	-$25.8K	﹤0.01%	1593
2019 Q3	$59K	Buy	13,154 +952	+8%	+$4.76K	﹤0.01%	1121
2019 Q2	$58K	Buy	12,202 +5,847	+92%	+$27.7K	﹤0.01%	1082
2019 Q1	$35K	Buy	+6,355	New	+$29.2K	﹤0.01%	1221
2018 Q2	–	Sell	-5,847	Closed	-$37K	–	2148
2018 Q1	$37K	Buy	+5,847	New	+$48.4K	﹤0.01%	1155
2015 Q2	–	Sell	-534	Closed	-$50K	–	2264
2015 Q1	$50K	Buy	534 +13	+2%	+$1.11K	0.01%	1289
2014 Q4	$46K	Sell	521 -2,184	-81%	-$159K	0.01%	1278
2014 Q3	$187K	Buy	2,705 +1,434	+113%	+$76.6K	0.03%	738
2014 Q2	$73K	Buy	+1,271	New	+$64.5K	0.01%	1234

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prelude Capital Management's MACK Position: Q4 2020 in Review

Prelude Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2020, closing a stake of 2,700 shares — an estimated $11K sold.

Prelude Capital Management first reported a position in MACK in Q2 2014 and held it in 11 quarters. The position peaked at $187K in Q3 2014. 40 funds tracked by Wall St. Rank hold MACK as of Q4 2020.

Prelude Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 2,700 Merrimack Pharmaceuticals, Inc. shares in Q4 2020, an estimated $11K.
Prelude Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
Prelude Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $187K in Q3 2014.
40 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.